Cardiovascular Drugs Practice Questions

Q: Which drug can be used to delay the progression of aortic dilatation in Marfan syndrome?

Propranolol. **Explanation:** **Marfan Syndrome** is a genetic connective tissue disorder caused by mutations in the *FBN1* gene, leading to weakened aortic walls. The primary cause of mortality is progressive aortic root dilatation, which leads to dissection or rupture. **Why Propranolol is correct:** Beta-blockers, specifically **Propranolol**, are the traditional first-line therapy to delay aortic dilatation. They work via two mechanisms: 1. **Negative Inotropic Effect:** They decrease the force of myocardial contraction ($dP/dt$), reducing the "hammering" effect of blood against the aortic root. 2. **Negative Chronotropic Effect:** By lowering the heart rate, they reduce the frequency of pulsatile stress on the weakened connective tissue. **Why the other options are incorrect:** * **Vitamin E:** An antioxidant that has no proven clinical benefit in preventing structural vascular changes in Marfan syndrome. * **ACE Inhibitors:** While they reduce afterload, they are not the primary choice for Marfan-related dilatation. However, **Losartan (an ARB)** is a significant alternative as it inhibits TGF-$\beta$ signaling, which is overactive in Marfan syndrome. * **Idebenone:** A synthetic analog of Coenzyme Q10 used primarily in Leber’s Hereditary Optic Neuropathy (LHON) and Friedreich's Ataxia; it has no role in aortic pathology. **High-Yield Clinical Pearls for NEET-PG:** * **First-line drugs:** Beta-blockers (Propranolol/Atenolol). * **Alternative/Adjunct:** Losartan (ARB) is increasingly used because it specifically targets the TGF-$\beta$ pathophysiology. * **Monitoring:** Annual echocardiography is mandatory to monitor aortic root diameter. * **Surgery:** Prophylactic aortic root replacement is indicated when the diameter exceeds **5.0 cm** (or 4.5 cm if there is a family history of dissection).

Q: Which of the following causes increased renin on prolonged use?

Enalapril. ### Explanation The correct answer is **Enalapril**. #### 1. Why Enalapril is Correct Enalapril is an **ACE Inhibitor (ACEi)**. The secretion of renin from the juxtaglomerular (JG) cells is regulated by a **negative feedback loop** mediated by Angiotensin II [2]. * **Mechanism:** ACE inhibitors block the conversion of Angiotensin I to Angiotensin II [1]. * **Result:** The loss of negative feedback by Angiotensin II causes the JG cells to compensate by increasing the production and release of **Renin** [2]. Therefore, all ACE inhibitors and Angiotensin Receptor Blockers (ARBs) lead to a reactive increase in plasma renin levels [1]. #### 2. Why Other Options are Incorrect * **Clonidine & Methyldopa (Option A & C):** These are **centrally acting alpha-2 agonists**. They decrease sympathetic outflow from the vasomotor center. Since renin release is stimulated by sympathetic activity (via $\beta_1$ receptors), these drugs **decrease** renin levels [3]. * **Beta-blockers (Option D):** Renin release is primarily mediated by **$\beta_1$ receptors** on the JG apparatus. Beta-blockers (like Propranolol or Atenolol) directly inhibit this mechanism, leading to a **decrease** in plasma renin levels [3]. #### 3. High-Yield Clinical Pearls for NEET-PG * **Renin Levels:** Increased by ACEis, ARBs, Diuretics (due to volume depletion), and Direct Vasodilators (Hydralazine) [1, 5]. Decreased by Beta-blockers, Clonidine, and NSAIDs (via prostaglandin inhibition). * **Aliskiren:** It is a **Direct Renin Inhibitor**. While it increases the *concentration* of renin (due to loss of feedback), it decreases **Plasma Renin Activity (PRA)**. * **ACEi Side Effects:** Remember the mnemonic **CAPTOPRIL** (Cough, Angioedema, Proteinuria, Taste changes, Orthostatic hypotension, Pregnancy contraindication, Renal artery stenosis contraindication, Increased potassium/Hyperkalemia, Leukopenia).

Q: Gemfibrozil is:

PPAR-alpha activator. **Explanation:** **Gemfibrozil** belongs to the **Fibrate** class of hypolipidemic drugs. Its primary mechanism of action is the activation of **Peroxisome Proliferator-Activated Receptor-alpha (PPAR-α)**, a nuclear receptor. 1. **Why Option B is Correct:** Activation of PPAR-α leads to increased transcription of genes involved in lipid metabolism. This results in: * **Increased Lipoprotein Lipase (LPL) activity:** Enhancing the clearance of triglyceride-rich lipoproteins (VLDL and chylomicrons). * **Increased Apo A-I and Apo A-II synthesis:** Leading to a rise in HDL ("good") cholesterol levels. * **Decreased Apo C-III synthesis:** (Apo C-III normally inhibits LPL), further facilitating triglyceride breakdown. 2. **Why Other Options are Incorrect:** * **Option A & C:** **HMG-CoA Reductase inhibitors** (Statins) are the drugs that inhibit the rate-limiting step of cholesterol synthesis. * **Option D:** **Ezetimibe** is the drug that specifically inhibits cholesterol absorption by targeting the NPC1L1 transporter in the small intestine. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Fibrates are the first-line treatment for **Severe Hypertriglyceridemia** (TG >500 mg/dL) to prevent acute pancreatitis. * **Adverse Effects:** Myopathy and gallstones (cholelithiasis) due to increased biliary cholesterol excretion. * **Drug Interaction:** Gemfibrozil inhibits the glucuronidation of **Statins**, significantly increasing the risk of **rhabdomyolysis** when used in combination. (Note: Fenofibrate is preferred over Gemfibrozil if a statin-fibrate combination is necessary).

Q: Enalapril is contraindicated in all of the following conditions except?

Diabetic nephropathy with albuminuria. **Explanation:** **Enalapril**, an ACE inhibitor (ACEi), is not only safe but is the **drug of choice** for **Diabetic Nephropathy with albuminuria**. 1. **Why Option A is correct:** In diabetic nephropathy, ACE inhibitors provide a **renoprotective effect**. They selectively dilate the **efferent arteriole** of the glomerulus, which reduces intraglomerular pressure and decreases protein excretion (albuminuria). This slows the progression of chronic kidney disease (CKD). 2. **Why other options are contraindications:** * **Bilateral Renal Artery Stenosis (and Single Kidney with Stenosis):** In these conditions, glomerular filtration rate (GFR) is maintained by high levels of Angiotensin II, which constricts the efferent arteriole. Giving Enalapril removes this compensatory constriction, leading to a precipitous drop in GFR and **acute renal failure**. * **Hyperkalemia:** ACE inhibitors reduce Aldosterone secretion (which normally promotes potassium excretion). Therefore, they cause potassium retention. Administering them in an already hyperkalemic patient can lead to life-threatening arrhythmias. **High-Yield Clinical Pearls for NEET-PG:** * **Teratogenicity:** ACE inhibitors are contraindicated in pregnancy as they cause fetal renal anomalies (Potter sequence) and skull hypoplasia. * **Side Effects:** The most common side effect is a **dry cough** (due to increased Bradykinin and Substance P). The most serious side effect is **Angioedema**. * **Monitoring:** When starting an ACEi, always monitor serum creatinine and potassium levels. A rise in creatinine up to 30% is acceptable; beyond that, the drug should be discontinued.

Q: Which drug should not be given in pregnancy?

ACE inhibitors. **Explanation:** **ACE inhibitors (e.g., Enalapril, Lisinopril)** are strictly contraindicated in pregnancy (Category X) because they are potent **teratogens**. Their mechanism involves blocking the Renin-Angiotensin-Aldosterone System (RAAS), which is crucial for fetal renal development. Exposure, particularly in the 2nd and 3rd trimesters, leads to **fetal renal dysgenesis**, which causes oligohydramnios (low amniotic fluid). This results in the **"Potter sequence"** (hypoplastic lungs, limb contractures, and cranial malformations) and fetal skull hypoplasia. **Analysis of Incorrect Options:** * **Methyldopa (Option D):** Historically the "gold standard" and safest drug for chronic hypertension in pregnancy. It is a centrally acting alpha-2 agonist with a long-standing safety profile. * **Labetalol (Option A):** Currently the first-line agent for both chronic hypertension and hypertensive emergencies in pregnancy due to its rapid onset and minimal side effects. * **Hydralazine (Option B):** A direct vasodilator commonly used for the acute management of severe hypertension or pre-eclampsia. **High-Yield Clinical Pearls for NEET-PG:** * **Safe Drugs in Pregnancy:** Remember the mnemonic **"Better Mother Care During Hypertensive-crisis"** (B-Labetalol, M-Methyldopa, C-Nifedipine/CCBs, D-Hydralazine). * **Teratogenic Effect:** ACE inhibitors and ARBs (Angiotensin Receptor Blockers) both cause **renal agenesis** and **skull defects**. * **Diuretics:** Generally avoided in pregnancy as they can decrease uteroplacental perfusion by reducing plasma volume. * **Statins and Warfarin:** Also contraindicated (Warfarin causes Fetal Warfarin Syndrome; Statins are teratogenic).

Q: Which of the following medications can cause cholelithiasis and choledocholithiasis?

Clofibrate. **Explanation:** **Clofibrate** (a first-generation Fibrate) is the correct answer. Fibrates act as **PPAR-α agonists**, which increase the activity of lipoprotein lipase. However, they also inhibit the enzyme **cholesterol 7α-hydroxylase**, which is the rate-limiting step in bile acid synthesis. This leads to: 1. **Decreased bile acid production:** Reducing the solubility of cholesterol in bile. 2. **Increased biliary cholesterol excretion:** Resulting in supersaturation of bile. This combination promotes the formation of cholesterol gallstones (**cholelithiasis**) and their subsequent migration into the common bile duct (**choledocholithiasis**). Due to this significant side effect profile, Clofibrate has largely been replaced by newer fibrates like Fenofibrate. **Incorrect Options:** * **Chloramphenicol:** Primarily associated with bone marrow suppression (dose-dependent) and **Gray Baby Syndrome** (due to deficient glucuronidation in neonates). * **Cotrimoxazole:** Commonly causes hypersensitivity reactions (Stevens-Johnson Syndrome), photosensitivity, and megaloblastic anemia (due to folate antagonism). * **Option D:** This is a clinical condition, not a medication, and does not have a direct causal link to gallstone formation in the context of pharmacological side effects. **High-Yield Clinical Pearls for NEET-PG:** * **Fibrates + Statins:** Combining these increases the risk of **myopathy and rhabdomyolysis** (Gemfibrozil is the worst offender as it inhibits statin glucuronidation). * **Drug of Choice:** Fibrates are the DOC for **Hypertriglyceridemia** (Type IV and V hyperlipoproteinemia). * **Other drugs causing gallstones:** Ceftriaxone (biliary sludge/pseudolithiasis) and Octreotide (inhibits gallbladder contractility).

Q: Ezetimibe acts by

Decreasing absorption of cholesterol. **Explanation:** **Ezetimibe** is a cholesterol absorption inhibitor that specifically targets the **Niemann-Pick C1-Like 1 (NPC1L1)** transport protein located on the brush border of enterocytes in the small intestine. By inhibiting this transporter, it reduces the delivery of dietary and biliary cholesterol to the liver. This leads to an upregulation of LDL receptors on hepatocytes, subsequently decreasing circulating LDL-C levels. **Analysis of Options:** * **Option A (Enhancing excretion of bile acids):** This is the mechanism of **Bile Acid Sequestrants** (e.g., Cholestyramine, Colestipol). They bind bile acids in the gut, preventing enterohepatic circulation and forcing the liver to use cholesterol to synthesize new bile acids. * **Option B (Correct):** Ezetimibe directly inhibits the intestinal absorption of cholesterol. * **Option C (Inhibiting HMG CoA reductase):** This is the mechanism of **Statins** (e.g., Atorvastatin). Statins inhibit the rate-limiting step of endogenous cholesterol synthesis. * **Option D (Inhibiting intracellular lipase):** This refers to the mechanism of **Fibrates** (which stimulate lipoprotein lipase) or **Niacin** (which inhibits hormone-sensitive lipase in adipose tissue). **High-Yield Clinical Pearls for NEET-PG:** * **Synergy:** Ezetimibe is frequently used as an "add-on" therapy to Statins. While Statins inhibit cholesterol *synthesis*, Ezetimibe inhibits cholesterol *absorption*, leading to a potent dual effect. * **Vytorin:** A fixed-dose combination of Ezetimibe + Simvastatin. * **Side Effects:** Generally well-tolerated; however, it may cause a mild increase in hepatic transaminases when used with statins. * **Key Target:** Always remember **NPC1L1** for Ezetimibe; it is a common "one-liner" question in PG exams.

Q: All of the following statements about lignocaine are true EXCEPT:

It is given orally for treatment of cardiac arrhythmias.. ### Explanation **Correct Answer: C. It is given orally for treatment of cardiac arrhythmias.** **Why Option C is the correct answer (The "Except" statement):** Lignocaine (Lidocaine) is a Class IB antiarrhythmic agent that undergoes **extensive first-pass metabolism** in the liver. If administered orally, its bioavailability is extremely low (approx. 30%), and its metabolites (monoethylglycinexylidide) can be toxic to the CNS. Therefore, for systemic effects like treating ventricular arrhythmias (e.g., post-MI), it must be administered **intravenously**. **Analysis of Incorrect Options:** * **Option A:** Lignocaine is a state-dependent sodium channel blocker. It has a higher affinity for **active (open) and inactivated states** of the sodium channel rather than the resting state. This property allows it to selectively block rapidly firing tissues (like ischemic myocardium). * **Option B:** While lignocaine is safer for the heart than bupivacaine, high systemic doses can lead to **cardiotoxicity**, manifesting as bradycardia, hypotension, and arrhythmias. * **Option C:** **Adrenaline (Epinephrine)** is a vasoconstrictor. When added to local anaesthetics for infiltration, it reduces local blood flow, thereby slowing the systemic absorption of lignocaine. This **increases the duration of action** and reduces systemic toxicity. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Lignocaine is the DOC for **ventricular arrhythmias** occurring during cardiac surgery or post-Myocardial Infarction. * **CNS Toxicity:** The initial signs of lignocaine toxicity are often neurological (perioral numbness, metallic taste, tremors, and seizures). * **Adrenaline Contraindication:** Never use lignocaine with adrenaline for "end-artery" areas like the **fingers, toes, tip of the nose, or penis**, as it can cause ischemic necrosis/gangrene. * **Metabolism:** It is metabolized by hepatic CYP3A4.

Question 1

Which drug can be used to delay the progression of aortic dilatation in Marfan syndrome?

Accepted Answer

Propranolol

Answer

Vitamin E

Answer

ACE inhibitor

Answer

Idebenone

Question 2

Which of the following causes increased renin on prolonged use?

Accepted Answer

Enalapril

Answer

Clonidine

Answer

Methyldopa

Answer

beta-blockers

Question 3

Gemfibrozil is:

Accepted Answer

PPAR-alpha activator

Answer

HMG CoA inhibitor

Answer

Inhibits cholesterol synthesis

Answer

Inhibits cholesterol absorption

Question 4

Enalapril is contraindicated in all of the following conditions except?

Accepted Answer

Diabetic nephropathy with albuminuria

Answer

Single kidney

Answer

Bilateral renal artery stenosis

Answer

Hyperkalemia

Question 5

Which drug should not be given in pregnancy?

Accepted Answer

ACE inhibitors

Answer

Labetalol

Answer

Hydralazine

Answer

Methyldopa

Question 6

Which of the following is the most beta-1 selective antagonist?

Accepted Answer

Bisoprolol

Answer

Acebutolol

Answer

Atenolol

Answer

Metoprolol

Question 7

Which of the following medications can cause cholelithiasis and choledocholithiasis?

Accepted Answer

Clofibrate

Answer

Chloramphenicol

Answer

Cotrimoxazole

Answer

Non-small cell lung cancer associated with AIDS

Question 8

Ezetimibe acts by

Accepted Answer

Decreasing absorption of cholesterol

Answer

Enhancing excretion of bile acids

Answer

Inhibiting HMG CoA reductase

Answer

Inhibiting intracellular lipase

Question 9

All of the following statements about lignocaine are true EXCEPT:

Accepted Answer

It is given orally for treatment of cardiac arrhythmias.

Answer

It blocks active sodium channels with more affinity than resting sodium channels.

Answer

It can cause cardiotoxicity.

Answer

Adrenaline increases the duration of action of lignocaine when used for infiltration anaesthesia.

Question 10

ACE inhibitors should not be used concurrently with which of the following agents?

Accepted Answer

Spironolactone

Answer

Amiloride

Answer

Calcium Channel Blockers (CCB)

Answer

Thiazides

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?